Skip to main content

Table 4 Rejection, infection, and other outcomes

From: A randomized controlled trial of daclizumab versus anti-thymocyte globulin induction for heart transplantation

 

ATG (n = 15)

DZM (n = 15)

p value

Mean biopsy grade

0.4

0.3

0.09

Patients experiencing rejection

2 (13%)

0

0.5

Total number of acute rejections

2

0

0.2

Time to first rejection episode (days)

84

-

-

Patients experiencing infection

10 (67%)

10 (67%)

1.0

Total number of infections

25

21

0.7

Infections/patient

1.7

1.4

0.7

Patients experiencing severe infection

4 (27%)

5 (33%)

1.0

Number of severe infections

7

7

1.0

Severe infections/patient

0.5

0.5

1.0

Number of CMV infections

1

2

1.0

Malignancy

0

1

1.0

Steroid-induced diabetes

2

2

1.0

Re-transplant

0

0

-

ICU length of stay (days)

11 ± 4

12 ± 4

09

Total hospital length of stay (days)

29 ± 8

27 ± 6

0.8

One-month survival

93%

100%

0.1

One-year survival

87%

87%

0.1